Management of patients presenting to the Emergency Department/ Acute Medicine with symptoms: Covid-19 Vaccine induced Thrombosis and Thrombocytopenia (VITT), RCEM/RCP/SAM
Guidance document on how to deal with a patient presenting to ED or acute medicine with COVID-19 vaccine-induced thrombosis and thrombocytopenia (VITT). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 19, 2021 Category: Consumer Health News Source Type: news

Management of patients presenting to the Emergency Department/ Acute Medicine with symptoms, RCEM
The condition of concern is Covid-19 Vaccine induced Thrombosis and Thrombocytopenia (VITT). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 16, 2021 Category: Consumer Health News Source Type: news

Guidance produced from the Expert Haematology Panel (EHP) focussed on Covid-19 Vaccine induced Thrombosis and Thrombocytopenia (VITT), British Society of Haematology
There are currently no robust data to inform management of this condition. In the absence of evidence, these are pragmatic guidelines based on experience of managing alternative similar conditions and the theoretical risks and benefits of interventions. As evidence emerges, recommendations are expected to change. Patient management should be individualised according to specific circumstances. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 16, 2021 Category: Consumer Health News Source Type: news

FDA and CDC Recommend Pausing COVID-19 Vaccination With J & J-Janssen Shot While They Investigate Blood Clot Risks
The U.S. Food and Drug Administration and Centers for Disease Control and Prevention are recommending that vaccinations with the Johnson & Johnson/Janssen COVID-19 vaccine be temporarily halted while the agencies review reports of blood clots among vaccinated people. On April 13, the two government agencies issued a joint statement announcing a recommended pause as federal regulators review six cases of blood clots reported six to 13 days after the people received the single-dose vaccine. “Until that [review] process is complete, we are recommending a pause in the use of this vaccine out of an abundance of cautio...
Source: TIME: Health - April 13, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Rare Thrombosis, Thrombocytopenia Seen After AstraZeneca COVID-19 Vaccine
TUESDAY, April 13, 2021 -- While rare, thrombosis and thrombocytopenia can occur after the ChAdOx1 nCoV-19 adenoviral vector vaccine against COVID-19 (AstraZeneca), according to two reports published online April 9 in the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 13, 2021 Category: Pharmaceuticals Source Type: news

Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). (Source: World Pharma News)
Source: World Pharma News - April 13, 2021 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

How worried should we be about blood clots linked to AstraZeneca and J & J vaccines?
With both the AstraZeneca and Johnson& Johnson (J&J)vaccines, the reports involve extremely rare clotting, including a type of blood clot called cerebral venous sinus thrombosis (CVST), that were seen in combination with low levels of blood platelets, called thrombocytopenia. (Source: The Economic Times)
Source: The Economic Times - April 13, 2021 Category: Consumer Health News Source Type: news

Two New Studies Point to How AstraZeneca ’s COVID-19 Vaccine Is Linked to Blood Clots
In two papers published in the New England Journal of Medicine (NEJM), researchers in Europe provide the most detailed explanation yet for what is behind the clotting side effects reported among people getting vaccinated with the AstraZeneca COVID-19 shot. In both papers, researchers found that people getting the vaccine had higher levels of antibodies directed against a cluster of immune-related cells that the body might form in response to the vaccine. These clusters include platelets, which help blood to clot when you get cut or injured, and the antibodies stick to the platelet-complex and form dangerous clots that can ...
Source: TIME: Health - April 9, 2021 Category: Consumer Health News Tags: Uncategorized COVID-19 Source Type: news

Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19, Frontiers in immunology
Sepsis is a life-threatening systemic illness attributed to a dysregulated host response to infection. Sepsis is a global burden killing ~11 million persons annually. In December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged and has resulted in more than 1,535,982 deaths globally as of 8 th December 2020. These two conditions share many pathophysiological and clinical features. Notably, both sepsis and COVID-19 patients experience consumptive thrombocytopenia, haemolytic anaemia, vascular microthrombosis, multi-o...
Source: Current Awareness Service for Health (CASH) - April 9, 2021 Category: Consumer Health News Source Type: news

EMA Again Reassures on AstraZeneca COVID Vaccine EMA Again Reassures on AstraZeneca COVID Vaccine
But the agency says it cannot rule out a link between rare and serious cases of thrombosis with thrombocytopenia with the vaccine.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 7, 2021 Category: Neurology Tags: Infectious Diseases News Source Type: news

AstraZeneca COVID Vaccine: Clotting Disorder Mechanism Revealed? AstraZeneca COVID Vaccine: Clotting Disorder Mechanism Revealed?
More information has become available indicating that the vaccine may be linked to a condition that clinically resembles heparin-induced thrombocytopenia and seems to occur mainly in younger women.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 1, 2021 Category: Cardiology Tags: Public Health & Prevention News Source Type: news

CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
Commercial Preparations Underway to Support Potential Approval and Launch of Pacritinib in the United States in 2021 SEATTLE, March 31, 2021 -- (Healthcare Sales & Marketing Network) -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has com... Biopharmaceuticals, FDA CTI BioPharma, pacritinib, myelofibrosis, thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 31, 2021 Category: Pharmaceuticals Source Type: news

Why Countries Around the World Are Suspending Use of AstraZeneca ’s COVID-19 Vaccine
It’s the last thing public health officials want to see in the midst of a pandemic: more than two months after pharmaceutical giant AstraZeneca and Oxford University scientists released their COVID-19 vaccine, countries in Europe and elsewhere are pausing its use amid disconcerting reports that a small number of recipients have experienced blood clots, some of them fatal. The European Medicines Agency, which oversees drugs and vaccines in Europe, is expected to issue a guidance on March 18 about whether the side effects were related to the vaccine after reviewing the reports; in the meantime, it says the benefits of ...
Source: TIME: Health - March 16, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Covid-19 vaccine safe, based on scientific evidence, AstraZeneca reassures the world
It further said that, a review of available safety data of more than 17 million people vaccinated in the European Union (EU) and UK with its vaccine has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia, in any defined age group, gender, batch or in any particular country. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 15, 2021 Category: Pharmaceuticals Source Type: news

Perioperative Platelet Transfusions Perioperative Platelet Transfusions
Platelet transfusion is the primary therapy for patients with thrombocytopenia or platelet dysfunction who require surgery. Review guidance on when and which type to use in this paper.Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 3, 2021 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news

mRNA vaccines for the Wuhan coronavirus caused blood disorder in at least 36 people
(Natural News) The messenger RNA (mRNA) vaccines developed to fight the Wuhan coronavirus may have caused at least 36 individuals to develop a rare blood disorder. Either Moderna’s mRNA-1273 jab or the Pfizer/BioNTech BNT162b2 vaccine may have caused thrombocytopenia – which affects blood clotting – in these individuals. Both vaccines had reported more than 90... (Source: NaturalNews.com)
Source: NaturalNews.com - February 11, 2021 Category: Consumer Health News Source Type: news

36 people developed rare blood disorder after covid vaccination
At least 36 people have developed a rare, life-threatening blood disorder, called thrombocytopenia, after receiving either of the two COVID-19 vaccines authorized in the US. (Source: the Mail online | Health)
Source: the Mail online | Health - February 9, 2021 Category: Consumer Health News Source Type: news

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to th...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Doctor's Death After Getting the Covid Vaccine Is Investigated
A Florida physician developed an unusual blood disorder shortly after he received the Pfizer vaccine. It is not yet known if the shot is linked to the illness. (Source: NYT Health)
Source: NYT Health - January 12, 2021 Category: Consumer Health News Authors: Denise Grady and Patricia Mazzei Tags: your-feed-healthcare Vaccination and Immunization Coronavirus (2019-nCoV) Coronavirus Risks and Safety Concerns Deaths (Fatalities) Centers for Disease Control and Prevention Hemorrhagic Stroke immune thrombocytopenia Pfizer Inc Michael, Source Type: news

Doctor's Death After Getting the Covid-19 Vaccine Is Investigated
A Florida physician developed an unusual blood disorder shortly after he received the Pfizer vaccine. It is not yet known if the shot is linked to the illness. (Source: NYT Health)
Source: NYT Health - January 12, 2021 Category: Consumer Health News Authors: Denise Grady and Patricia Mazzei Tags: your-feed-healthcare Vaccination and Immunization Coronavirus (2019-nCoV) Coronavirus Risks and Safety Concerns Deaths (Fatalities) Centers for Disease Control and Prevention Hemorrhagic Stroke immune thrombocytopenia Pfizer Inc Michael, Source Type: news

Mycophenolate Shows Promise in Immune Thrombocytopenia Mycophenolate Shows Promise in Immune Thrombocytopenia
For patients with immune thrombocytopenia, adding mycophenolate to the standard of care (steroids) resulted in half as many treatment failures as steroids alone.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - December 14, 2020 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news

No Benefit From Tranexamic Acid Prophylaxis in Blood Cancers No Benefit From Tranexamic Acid Prophylaxis in Blood Cancers
Tranexamic acid prophylaxis did not reduce bleeding among patients with hematologic malignancies and severe thrombocytopenia and may do more harm than good.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 7, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with ...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
This study evaluated the ability of teclistamab to induce cytotoxicity and T-cell activation.About TeclistamabTeclistamab is an investigational bispecific antibody targeting both BCMA and CD3. BCMA, B-cell maturation antigen, is expressed at high levels on multiple myeloma cells.[3],[4],[5],[6],[7] Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce cytotoxicity of the targeted cells.5,6 Results from preclinical studies demonstrate that teclistamab kills myeloma cell lines and bone marrow-derived myeloma cells from heavily pretreated patients.6 Teclistamab is currently being evaluated in a...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. These data, presented as an oral presentation at the American Society of Hematology (ASH) 2020 Annual Meeting (Abstract #177), continued to demonstrate a very hig...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized ...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Rigel and Medison Announce Health Canada Approval of TAVALISSE(R), an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
SOUTH SAN FRANCISCO, Calif. and PETACH TIKVA, Israel, Nov. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Medison Pharma (Medison) today announced that Health Canada has approved the new drug submissio... Biopharmaceuticals, Regulatory Rigel Pharmaceuticals, Medison Pharma, TAVALISSE, fostamatinib, thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 23, 2020 Category: Pharmaceuticals Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

CBD for LGS: Fewer Seizures, Increased Thrombocytopenia Risk CBD for LGS: Fewer Seizures, Increased Thrombocytopenia Risk
Two recent analyses of highly purified cannabidiol (CBD) used to reduce seizures in Lennox Gastaut syndrome (LGS) have shown it is effective in reducing seizures for 3 years.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 23, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
SEATTLE, Oct. 13, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has commenced a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration ( " FDA " or " the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - October 13, 2020 Category: Drugs & Pharmacology Source Type: news

What Are the Clinical Signs and Symptoms of Congenital Syphilis?
Discussion Syphilis is caused by the spirochete Treponema pallidum. It is a very old disease that despite understanding the organism and readily available treatment, still causes disease. Syphilis is transmitted sexually. According to the Centers for Disease Control, “[i]n 2018, a total of 35,063 cases of [Primary and Secondary] syphilis were reported in the United States, yielding a rate of 10.8 cases per 100,000 population …. This rate represents a 14.9% increase compared with 2017 (9.4 cases per 100,000 population), and a 71.4% increase compared with 2014 (6.3 cases per 100,000 population).” The incre...
Source: PediatricEducation.org - September 28, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Prognosis and rescue therapy for sepsis-related severe thrombocytopenia in critically ill patients
This study aims to explore the effect of severe thrombocytopenia on the prognosis of sepsis and the impact of a platelet-elevating drug (recombinant human thrombopoietin, rhTPO) for these sepsis patients. In this study, we included 249 sepsis patients diagnosed by sepsis 3.0, and these patients were classified into the three groups based on PC: normal (PC>= 100 x 109/L), mild-moderate thrombocytopenia (50 x 109/L (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 3, 2020 Category: Consumer Health News Source Type: news

Pediatric Radiological Case: Autoimmune Hepatitis Pediatric Radiological Case: Autoimmune Hepatitis
Review the imaging studies that led to the diagnosis of autoimmune hepatitis in this 11-year-old who presented with abnormal liver function tests, thrombocytopenia, and hypoalbuminemia.Applied Radiology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - July 28, 2020 Category: Radiology Tags: Radiology Journal Article Source Type: news

What Are Some Pediatric Oncological Emergencies?
Discussion Pediatric cancers in the US number about 12,000 per year. After injury, it is the second leading cause of death in children and adolescents. Cancer presentations vary widely, but often begin with non-specific symptoms that continue or progress depending on the location and tumor type. Patients can present with oncological emergencies especially if there are mechanical obstruction such as superior vena cava syndrome or cerebral herniation. More commonly are infections due to immunosuppression. Cancer treatment also causes its own myriad of problems that clinicians need to be aware of to diagnosis and treat, but a...
Source: PediatricEducation.org - July 20, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020
Basel, 13 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III VIALE-A study, evaluating Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. VIALE-A results were featured in the 25th European Hematology Association Virtual Congress Press Briefing on Saturda y 13 June 2020 at 08:30 CEST and will be presented at the congress during the Late-breaking Oral Session (abstract #LB2601) on Sunday 14 June 2020.“We are very pleased to p...
Source: Roche Media News - June 13, 2020 Category: Pharmaceuticals Source Type: news

Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020
Basel, 13 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III VIALE-A study, evaluating Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. VIALE-A results were featured in the 25th European Hematology Association Virtual Congress Press Briefing on Saturda y 13 June 2020 at 08:30 CEST and will be presented at the congress during the Late-breaking Oral Session (abstract #LB2601) on Sunday 14 June 2020.“We are very pleased to p...
Source: Roche Investor Update - June 13, 2020 Category: Pharmaceuticals Source Type: news

Janssen ’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-4528, an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy in the treatment of patients with relapsed or refractory multiple myeloma. Longer-term follow-up results from the Phase 1b portion of the study (n=29), to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #8505), show t...
Source: Johnson and Johnson - May 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Falling Splenectomy Rates in ITP Raise Questions Over Role Falling Splenectomy Rates in ITP Raise Questions Over Role
Splenectomy is being performed less and less often in immune thrombocytopenia due to the increased availability of medical therapies, resulting in a lower benefit of the procedure to patients, suggests UK data.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 11, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Clinical characteristics and predictors of outcomes of hopsitalised patients with Covid-19 in a London NHS trust: a retrospective cohort study
This report is one of the first studies to describe the characteristics and predictors of outcomes for hospitalised Covid-19 patients in the UK. It finds that older age, male sex and admission hypoxia, thrombocytopenia, renal failure, hypoalbuminaemia and raised bilirubin are associated with increased odds of death. Ethnic minority groups were over-represented in the cohort and, compared to white people, people of black ethnicity may be at increased odds of mortality. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 11, 2020 Category: Consumer Health News Source Type: news

Clinical characteristics and predictors of outcomes of hospitalised patients with Covid-19 in a London NHS trust: a retrospective cohort study, Imperial College London
This report is one of the first studies to describe the characteristics and predictors of outcomes for hospitalised Covid-19 patients in the United Kingdom. It finds that older age, male sex and admission hypoxia, thrombocytopenia, renal failure, hypoalbuminaemia and raised bilirubin are associated with increased odds of death. Minority ethnic groups were over-represented in the cohort and, compared to white people, people of black ethnicity may be at increased odds of mortality. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 6, 2020 Category: Consumer Health News Source Type: news

U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
HORSHAM, Pa., April 21, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy. The approval is based on positive results from the landmark Phase 3 E1912 study that was designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute, part of the National Institutes of Health. Today’s mi...
Source: Johnson and Johnson - April 22, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

A Case of Chronic Thrombocytopenia in a 17-Year-Old Female A Case of Chronic Thrombocytopenia in a 17-Year-Old Female
A case of gray platelet syndrome, a rare type of thrombocytopenia, is discussed. How is this disorder diagnosed and treated?Laboratory Medicine (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 12, 2020 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “W...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Amanita fuliginea poisoning with thrombocytopenia: a case series - Wang Q, Sun M, Lv H, Lu P, Ma C, Liu Y, Liu S, Tong H, Hu Z, Gao Y.
We present 3 cases of severe A. fuliginea poisoning associated with thrombocytopenia in China. Three patients consumed foraged A. fuliginea and developed nau... (Source: SafetyLit)
Source: SafetyLit - February 3, 2020 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news

Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma
This case of severe grade V thrombocytopenia caused by nivolumab highlights the need for clinicians to be aware of this potential adverse effect of immune-checkpoint inhibitors.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 14, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia
DURHAM, N.C., Jan. 13, 2020 -- (Healthcare Sales & Marketing Network) -- Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), has been granted Orphan Drug Designation1 (ODD) by the US Food and Drug Administr... Biopharmaceuticals, Oncology, FDA Dova Pharmaceuticals, avatrombopag, Chemotherapy-Induced, Thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 13, 2020 Category: Pharmaceuticals Source Type: news

Avatrombopag cost  effective for thrombocytopenia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 31, 2019 Category: Drugs & Pharmacology Source Type: news

Romiplostim for Chemotherapy-Induced Thrombocytopenia Romiplostim for Chemotherapy-Induced Thrombocytopenia
Does the thrombopoietin receptor agonist romiplostim expedite correction of thrombocytopenia caused by chemotherapy?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news